Onderzoeksklasse Etokimab

ANB020, nowcalledetokimab, iscurrentlyinphase2atestingineczema, whichisalsoknownasatopicdermatitis.ScientistsfromtheMedicalResearchCouncilHumanImmunologyUnitattheUniversityofOxfordreleaseddatafrom12patientsshowingthat83%whoweretreatedwithetokimabreportedareductionindiseaseseverityafter29days.Etokimab, ananti-IL-33biologic, haspreviouslydemonstratedagoodsafetyprofileandfavorablepharmacodynamicpropertiesinmanyclinicalstudies.Etokimabisdesignedtoblockinterleukin-33 (IL-33), animmune-signalingmolecule.Inpeanutallergy, thebodyoverreactstopeanutsasIL-33activatesanantibodycalledimmunoglobinE.Theseantibodiescauseallergicresponsesuchasmouthitchiness, hives, breathingdifficultiesandpotentiallyfatalanaphylacticshock.

ANB020, CAS:2022981-44-6, IL33

Mammalian Cells

NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1familymember11, IL33, Nuclearfactorfromhighendothelialvenules, NFHEV, Interleukin-33, IL1F11

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -110°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-kappa